文献速递哮喘

2型相关合并症与重症哮喘生物制剂疗效的关联

Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

该队列研究利用国际重症哮喘登记处21国2017-2022年数据,纳入1765例成人重症哮喘患者,评估过敏性鼻炎、慢性鼻窦炎伴或不伴鼻息肉、鼻息肉、湿疹/特应性皮炎等2型相关合并症与生物制剂疗效的关联。结果显示,合并慢性鼻窦炎伴或不伴鼻息肉者生物制剂治疗后急性发作率更低、哮喘控制更优、FEV1%预计值改善更明显;过敏性鼻炎或特应性皮炎与疗效无关。

要点

  • 合并慢性鼻窦炎伴或不伴鼻息肉的重症哮喘患者,生物制剂治疗后年急性发作率降低23%(95%CI 10-35%)。
  • 上述患者生物制剂治疗后哮喘控制改善的比值比为59%(95%CI 26-102%)。
  • 过敏性鼻炎或特应性皮炎与生物制剂疗效无关,提示应系统评估合并症。

核心结论

  • 合并慢性鼻窦炎伴或不伴鼻息肉或单纯鼻息肉可能预测重症哮喘患者对生物制剂的疗效。
  • 过敏性鼻炎或特应性皮炎与生物制剂治疗后任何结局的疗效无关。

研究设计与样本

  • 国际重症哮喘登记处(ISAR)数据,21个国家,2017-2022年。
  • 纳入1765例成人重症哮喘患者,其中1257例起始抗IL-5/5R治疗,421例抗IgE治疗,87例抗IL-4/13治疗。
  • 比较有无过敏性鼻炎、慢性鼻窦炎伴或不伴鼻息肉、鼻息肉、湿疹/特应性皮炎患者的生物制剂治疗前后四个结局变化。

主要发现

  • 无论合并症状态如何,生物制剂治疗前后四个哮喘结局(年急性发作率、FEV1%预计值、哮喘控制、长期口服糖皮质激素日剂量)总体均有改善。
  • 合并慢性鼻窦炎伴或不伴鼻息肉者较无此合并症者年急性发作率降低23%(95%CI 10-35%;P<0.001),哮喘控制改善的比值比高59%(95%CI 26-102%;P<0.001)。
  • 合并鼻息肉者年急性发作率降低22%,哮喘控制改善的比值比高56%。
  • 合并慢性鼻窦炎伴或不伴鼻息肉者FEV1%预计值额外改善3.2%(95%CI 1.0-5.3;P=0.004),合并鼻息肉者也有类似趋势。
  • 过敏性鼻炎或特应性皮炎与生物制剂治疗后任何评估结局均无关联。

临床怎么用

  • 对重症哮喘患者应系统评估2型相关合并症,尤其是慢性鼻窦炎和鼻息肉。
  • 合并慢性鼻窦炎伴或不伴鼻息肉或单纯鼻息肉可作为生物制剂疗效的预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Previous studies investigating the impact of comorbidities on the effectiveness of biologic agents have been relatively small and of short duration and have not compared classes of biologic agents. Objectives: To determine the association between type 2-related comorbidities and biologic agent effectiveness in adults with severe asthma (SA). Methods: This cohort study used International Severe Asthma Registry data from 21 countries (2017-2022) to quantify changes in four outcomes before and after biologic therapy-annual asthma exacerbation rate, FEV1% predicted, asthma control, and long-term oral corticosteroid daily dose-in patients with or without allergic rhinitis, chronic rhinosinusitis (CRS) with or without nasal polyps (NPs), NPs, or eczema/atopic dermatitis. Measurements and Main Results: Of 1,765 patients, 1,257, 421, and 87 initiated anti-IL-5/5 receptor, anti-IgE, and anti-IL-4/13 therapies, respectively. In general, pre- versus post-biologic therapy improvements were noted in all four asthma outcomes assessed, irrespective of comorbidity status. However, patients with comorbid CRS with or without NPs experienced 23% fewer exacerbations per year (95% CI, 10-35%; P < 0.001) and had 59% higher odds of better post-biologic therapy asthma control (95% CI, 26-102%; P < 0.001) than those without CRS with or without NPs. Similar estimates were noted for those with comorbid NPs: 22% fewer exacerbations and 56% higher odds of better post-biologic therapy control. Patients with SA and CRS with or without NPs had an additional FEV1% predicted improvement of 3.2% (95% CI, 1.0-5.3; P = 0.004), a trend that was also noted in those with comorbid NPs. The presence of allergic rhinitis or atopic dermatitis was not associated with post-biologic therapy effect for any outcome assessed. Conclusions: These findings highlight the importance of systematic comorbidity evaluation. The presence of CRS with or without NPs or NPs alone may be considered a predictor of the effectiveness of biologic agents in patients with SA.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Wechsler, Scelo, Larenas-Linnemann, et al. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma. Am J Respir Crit Care Med. 2024. PMID: 38016003. doi:10.1164/rccm.202305-0808OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。